GLP-1 & Weight Loss Research Hub
GLP-1 Receptor Agonists: Semaglutide, Tirzepatide & Beyond
The definitive research collection on GLP-1 receptor agonists — from the foundational science of semaglutide to next-generation dual and triple agonists like tirzepatide, retatrutide, and CagriSema.
Class
Incretin Hormone Analogues
Primary Target
GLP-1 Receptor (GLP1R)
Research Focus
Metabolic & Weight Research
Latest Generation
Triple Agonists (GLP-1/GIP/GCG)
All GLP-1 Articles
23 articlesSemaglutide: A GLP-1 Receptor Agonist in Metabolic and Obesity Research
An exploration of Semaglutide, a GLP-1 receptor agonist, focusing on its molecular characteristics, mechanism of action, and diverse research applications in metabolic and obesity studies within experimental models.
AOD-9604: Investigating a Synthetic Peptide in Fat Metabolism Research
AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH176-191) studied in experimental models for its role in fat metabolism and lipolysis, without the growth-promoting effects associated with full-length hGH.
Tirzepatide: A Dual GIP/GLP-1 Receptor Agonist in Metabolic and Obesity Research
Tirzepatide is a synthetic dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Preclinical and clinical research has demonstrated significant reductions in body weight and improvements in glycemic control, positioning it as a subject of intense metabolic research.
Retatrutide: Triple Receptor Agonism in Next-Generation Obesity and Metabolic Research
Retatrutide is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Early-phase clinical research has reported unprecedented weight loss magnitudes, positioning it as one of the most potent anti-obesity compounds currently under investigation.
AOD-9604 vs. Semaglutide: Different Mechanisms in Metabolic Research
A comparison of AOD-9604 and Semaglutide as research tools in metabolic studies, examining their distinct mechanisms of action, published evidence, and appropriate research applications.
Best Peptides for Metabolic Research: AOD-9604, Semaglutide, MOTS-c, and Tirzepatide
A research-focused overview of peptides studied for metabolic effects, including mechanisms of action, published study findings, and key differences between GLP-1 receptor agonists, lipolytic fragments, and mitochondrial regulators.
Semaglutide vs. Tirzepatide: Mechanisms, Clinical Trial Data, and Research Distinctions
A detailed research comparison of semaglutide (GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist), covering receptor pharmacology, clinical trial outcomes, and the mechanistic basis for their differing efficacy profiles.
Weight Loss Peptides Compared: AOD-9604, Semaglutide, Tirzepatide Research
A comparative overview of the major research peptides studied for weight loss and metabolic research, examining their mechanisms, evidence bases, and relative efficacy.
AOD-9604: The C-Terminal Fragment of HGH and Fat Metabolism Research
A review of AOD-9604's origin as a fragment of human growth hormone, its documented lipolytic effects, and the published clinical evidence from Metabolic Pharmaceuticals' trials.
Tirzepatide vs Semaglutide: Dual Agonist vs Single Agonist Research
A mechanistic and clinical comparison of Tirzepatide (dual GLP-1/GIP agonist) and Semaglutide (GLP-1 agonist) based on published Phase III trial data.
Tesamorelin vs. Semaglutide: A Research-Focused Comparison
A detailed comparison of Tesamorelin (a GHRH analogue) and Semaglutide (a GLP-1 receptor agonist) across mechanism of action, metabolic effects, body composition findings, and research applications in experimental models.
Retatrutide (LY3437943): The Triple Hormone Receptor Agonist Reshaping Metabolic Research
Research overview of retatrutide (LY3437943), Eli Lilly's GLP-1/GIP/glucagon triple agonist. Covers mechanism of action, TRIUMPH Phase 3 trial data, and metabolic research applications.
CagriSema: Cagrilintide + Semaglutide Combination Research and the Amylin-GLP-1 Dual Pathway
Research overview of CagriSema -- Novo Nordisk's cagrilintide + semaglutide combination. Covers the dual amylin/GLP-1 mechanism, REDEFINE Phase 3 trial results, and metabolic research significance.
Ozempic vs. Wegovy vs. Mounjaro: A Research Comparison
Ozempic, Wegovy, and Mounjaro share overlapping mechanisms but differ in approved indications, dosing, and receptor targets — a research-focused comparison of semaglutide vs. tirzepatide formulations.
GLP-1 Receptor Agonism: Mechanism of Action Deep Dive
A detailed mechanistic review of GLP-1 receptor agonism — covering pancreatic beta-cell signaling, hypothalamic appetite suppression, gastric emptying delay, and cardiovascular protection pathways.
Peptide Stacking for Fat Loss: Research Protocols and Combinations
Research overview of peptide stacking strategies for fat loss — covering GLP-1 + GIP combinations, GH secretagogue stacks, and the mechanistic rationale for combining AOD-9604 with metabolic peptides.
Semaglutide for Weight Loss: Mechanisms, Trials, and Research Findings
Comprehensive research review of semaglutide's weight loss mechanisms, covering the STEP trial program, CNS appetite suppression pathways, and the SELECT cardiovascular outcomes data published in 2023.
Tirzepatide vs. Semaglutide: Which Should Researchers Study?
A research-design perspective on choosing between tirzepatide and semaglutide for metabolic studies — comparing receptor targets, trial outcomes, mechanistic novelty, and practical research considerations.
Buying Semaglutide for Research: Supplier Standards and What to Verify
A research-focused guide to sourcing semaglutide for laboratory use — covering purity standards, COA requirements, the difference between research-grade and pharmaceutical formulations, and supplier due diligence.
AOD-9604 Research Overview: GH Fragment and Fat Metabolism
A research overview of AOD-9604, a synthetic fragment of human growth hormone (hGH 176-191) studied for its effects on fat metabolism, lipolysis, and adipogenesis without the growth-promoting effects of full-length GH.
Retatrutide Research Overview: Triple Agonist GLP-1/GIP/Glucagon for Weight Loss
A research overview of retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, with a review of Phase 2 clinical trial results showing up to 24% body weight reduction.
Tesamorelin Research Overview: FDA-Approved GHRH Analogue for Visceral Fat
A research overview of tesamorelin, an FDA-approved GHRH analogue studied for visceral adiposity reduction in HIV-associated lipodystrophy, with a review of clinical trials, mechanisms, and research applications.
Semaglutide vs. Tirzepatide vs. Retatrutide: The Complete Research Comparison
A definitive research comparison of the three generations of GLP-1 class weight loss peptides — semaglutide (GLP-1), tirzepatide (GLP-1+GIP), and retatrutide (GLP-1+GIP+glucagon) — covering mechanisms, clinical trial data, and metabolic effects.
FOR RESEARCH PURPOSES ONLY — All content in this hub is intended strictly for scientific and educational reference. These compounds are not approved for human or animal consumption. Pure Pharm Peptides sells exclusively to qualified researchers.